GT200100079A - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
GT200100079A
GT200100079A GT200100079A GT200100079A GT200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A GT 200100079 A GT200100079 A GT 200100079A
Authority
GT
Guatemala
Prior art keywords
ryk
disease
protein
regulating angiogenesis
angiogenesis
Prior art date
Application number
GT200100079A
Other languages
English (en)
Spanish (es)
Inventor
Steve Rockzniak
Nathalie A Dubois-Stringfellow
Alya Zolotorev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100079A publication Critical patent/GT200100079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GT200100079A 2000-05-10 2001-05-07 Metodo para regular la angiogenesis utilizando proteina ryk GT200100079A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
GT200100079A true GT200100079A (es) 2001-12-31

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100079A GT200100079A (es) 2000-05-10 2001-05-07 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (de)
JP (1) JP2004527206A (de)
AR (1) AR028424A1 (de)
AU (1) AU2001261343A1 (de)
CA (1) CA2408349A1 (de)
CO (1) CO5300464A1 (de)
DO (1) DOP2001000164A (de)
EC (1) ECSP014068A (de)
GT (1) GT200100079A (de)
PE (1) PE20011218A1 (de)
SV (1) SV2002000442A (de)
UY (1) UY26696A1 (de)
WO (1) WO2001085789A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066087A2 (en) * 2002-02-06 2003-08-14 Developgen Aktiengesellschaft Für Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
NZ300808A (en) * 1994-12-23 1999-04-29 Ludwig Inst Cancer Res A method of detecting a ligand capable of binding the receptor protein nyk
ATE321856T1 (de) * 1998-06-11 2006-04-15 Humane rezeptortyrosinkinase
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4

Also Published As

Publication number Publication date
PE20011218A1 (es) 2002-02-01
UY26696A1 (es) 2001-12-28
EP1287121A2 (de) 2003-03-05
CA2408349A1 (en) 2001-11-15
WO2001085789A2 (en) 2001-11-15
CO5300464A1 (es) 2003-07-31
DOP2001000164A (es) 2002-05-15
WO2001085789A3 (en) 2002-05-16
AU2001261343A1 (en) 2001-11-20
JP2004527206A (ja) 2004-09-09
ECSP014068A (es) 2002-02-25
SV2002000442A (es) 2002-07-03
AR028424A1 (es) 2003-05-07

Similar Documents

Publication Publication Date Title
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ES2166783T3 (es) Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii.
ATE531382T1 (de) Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
ES2158115T3 (es) Derivados de histidina y homohistidina como inhibidores de la farnesiltransferasa de proteinas.
DE60237431D1 (de) Rezeptor-selektive cannabimimetische aminoalkylindole
CL2004001642A1 (es) Uso de un hidrolizado de proteina de pescado util para elaborar composiciones farmaceuticas y nutricionales, metodo de elaboracion de dicho hidrolizado.
CY1107248T1 (el) Συντηγμενες πρωτεϊνες
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
AR039947A1 (es) Formulacion farmaceutica que comprende nicotina
EA200900272A1 (ru) Комбинации для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
ATE365550T1 (de) Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
AR030631A1 (es) Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
ES2157422T3 (es) Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
DE50306682D1 (de) Synergistische kombination von seidenproteinen
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
BRPI0407611A (pt) agente anti-cáncer compreendendo proteìna lk8 como um ingrediente ativo
ATE556134T1 (de) Mesenchymstammzellen und verwendungendafür
GT200100079A (es) Metodo para regular la angiogenesis utilizando proteina ryk
PT1343472E (pt) Pulverizacao nasal tixotropica
EA200401586A1 (ru) Композиции для терапевтического использования, включающие витамин а, соль металла и инсулин либо гормон роста
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ATE374048T1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
DE60217292D1 (de) Veterinärmedizinische dermatologische zusammensetzung
SV2002000362A (es) Proteinas que tienen una actividad moduladora de angiogenesis ref.msb-7265-sv